Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era

被引：2
|
作者：
Liang, Xiping [1 ]
Hu, Renzhi [1 ]
Li, Qiying [1 ]
Wang, Chaoyu [1 ]
Liu, Yao [1 ]
机构：
[1] Chongqing Univ, Dept Hematol Oncol, Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis & I, Chongqing, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY | 2023年 / 122卷
关键词：
NCCN-IPI; EXPRESSION; CLASSIFICATION; BIOMARKER; SURVIVAL; ACCURATE; SUBTYPES; MARKER; DNA;
D O I：
10.1016/j.exphem.2023.03.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1 / 9
页数：9
相关论文
共 50 条
  • [1] Diffuse large B cell lymphoma: prognostic factors in the rituximab era
    Guevara Arismendy, Natalia Maria
    Jaramillo Arbelaez, Patricia Elena
    Gaviria Jaramillo, Lina Maria
    IATREIA, 2013, 26 (03) : 302 - 312
  • [2] Prognostic factors in diffuse large B-cell lymphoma
    Niitsu, Nozomi
    INTERNAL MEDICINE, 2006, 45 (05) : 227 - 228
  • [3] Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era
    Vaidya, R.
    Witzig, T. E.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2124 - 2133
  • [4] Molecular prognostic factors in diffuse large B-cell lymphoma
    Morgensztern D.
    Lossos I.S.
    Current Treatment Options in Oncology, 2005, 6 (4) : 269 - 277
  • [5] Outcome and prognostic factors in diffuse large B-cell lymphoma
    Mahajan, R.
    Yadav, B. S.
    Kumar, S.
    Gupta, A.
    Ghoshal, S.
    Sharma, S. C.
    Kumar, N.
    Kapoor, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Clinical Prognostic Models in Diffuse Large B-Cell Lymphoma Patients Are Still Essential in the Rituximab Era
    de Padua Covas Lage, Luis Alberto
    Costa, Renata Oliveira
    Hallack Neto, Abrahao Elias
    Siqueira, Sheila
    Santucci, Rodrigo
    de Paula, Henrique Moura
    Pereira, Juliana
    BLOOD, 2014, 124 (21)
  • [7] CLINICAL SIGNIFICANCE OF BIOMARKERS OF DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA
    Niitsu, N.
    Hayama, M.
    Hagiwara, Y.
    Tanae, K.
    Kohri, M.
    Takahashi, N.
    ANNALS OF ONCOLOGY, 2011, 22 : 154 - 154
  • [8] The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
    T Kobayashi
    J Kuroda
    I Yokota
    K Tanba
    T Fujino
    S Kuwahara
    R Isa
    J Yamaguchi
    E Kawata
    T Akaogi
    H Uchiyama
    H Kaneko
    N Uoshima
    Y Kobayashi
    S Teramukai
    M Taniwaki
    Blood Cancer Journal, 2016, 6 : e383 - e383
  • [9] Prognostic Significance of EBV Association in Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Niitsu, Nozomi
    Takahashi, Naoki
    Yoshino, Tadashi
    Okamoto, Masataka
    Nakamura, Shigeo
    BLOOD, 2015, 126 (23)
  • [10] The Kyoto Prognostic Index for Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Kobayashi, Tsutomu
    Kuroda, Junya
    Yokota, Isao
    Tanba, Kazuna
    Taki, Tomohiko
    Fujino, Takahiro
    Kuwahara, Saeko
    Isa, Reiko
    Yamaguchi, Junko
    Kawata, Eri
    Akaogi, Teruaki
    Uchiyama, Hitoji
    Kaneko, Hiroto
    Uoshima, Nobuhiko
    Kobayashi, Yutaka
    Teramukai, Satoshi
    Taniwaki, Masafumi
    BLOOD, 2015, 126 (23)
12345